ACHE and Alzheimer disease: Our group recently described, within this framework, the in vitro and in vivo properties of donecopride, the first MTDL able to both inhibit AChE and to activate 5-HT4 receptors (5-HT4R) with potent antiamnesic effects in animal models of AD [4,5].